UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~July 47, 2026

CONEXEU SCIENCES INC.
(Exact name of registrant as specified in its charter)

Nevada	001-43283	33-4814282
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

50 West Liberty Street, Suite 880,
Reno, Nevada, United States 89501
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (424) 333-5622

Not ~~Applicable~~applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock		CNXU		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~__________~~SECTION 7 - REGULATION FD

~~SECTION~~Item 37.01 -Regulation ~~SECURITIES~~FD ~~AND TRADING MARKETS~~Disclosure

~~Item~~On 3July 7, 2026, Conexeu Sciences Inc.02 ~~Unregistered~~(the ~~Sale~~"Company" or "Conexeu") issued a news release to announce the completion of ~~Equity~~the ~~Securities~~P.R.O.O.F phase (Performance and Regeneration Outcomes of Flowable Collagen) of the preclinical program for its CXUTM platform. The completed phase provides the evidence base the Company has been building toward as it prepares for a focused first move into medical aesthetics.

~~Exercise~~Study ~~of Common Stock Purchase Warrants and Warrant Exercise Incentive Program~~Highlights

On• P.R.O.O.F ~~June~~study 4complete, ~~2026,~~marking ~~Conexeu~~an ~~Sciences~~important ~~Inc~~catalyst. ~~(the~~Conexeu ~~"Registrant"~~has orcompleted ~~the~~its ~~"Company")~~P.R.O.O.F ~~issued 416,667 shares of common stock~~ (~~the~~Performance ~~"Warrant~~and ~~Shares"),~~Regeneration ~~upon~~Outcomes ~~the exercise~~ of aFlowable ~~like~~Collagen) ~~number~~preclinical ofprogram, ~~issued~~which ~~and~~provides ~~outstanding~~the ~~common~~evidence ~~stock~~base ~~purchase~~behind ~~warrants (~~the ~~"Warrants"),~~CXU™ ~~for~~platform's ~~gross~~development ~~proceeds~~direction ofand ~~approximately~~the ~~$166,667. The~~ Company's ~~intends~~planned tomove ~~use~~into the ~~proceeds~~medical ~~for~~aesthetics ~~general~~injectable ~~working capital purposes~~market.

~~The~~• What ~~Warrants~~the ~~were~~study ~~subject~~showed. toConexeu's a12-month ~~warrant~~preclinical ~~exercise~~study ~~incentive~~demonstrated: ~~program~~ (~~the~~i) ~~"Incentive~~objectives ~~Program")~~met ~~adopted~~for bytissue restoration in a small-volume facial model, specifically the ~~Company~~cheek; ~~with~~(ii) ~~effect~~objectives ~~from~~met ~~October~~for ~~31,~~tissue ~~2025,~~restoration in ~~order~~a tolarge-volume, ~~encourage~~200cc-equivalent ~~the~~model; ~~early~~and ~~exercise~~(iii) ofperformance upbenchmarks tomet ~~5,733,226~~for ofa ~~the~~deliverable ~~Company's~~injectable. ~~outstanding~~Full ~~common~~12-month ~~stock~~results ~~purchase~~are ~~warrants~~being ~~(the~~prepared ~~"Program~~for ~~Warrants")~~peer-reviewed publication.

~~Pursuant~~• What to the ~~Incentive~~benchmarks ~~Program,~~mean. To meet the ~~Company~~minimum ~~has~~market ~~offered~~standard asfor an ~~inducement~~aesthetic toinjectable, ~~each Program Warrant holder who exercises~~ a ~~Program~~material ~~Warrant~~must ~~not~~clear ~~later~~two ~~than~~key 4mechanical thresholds:00 ~~p.m.~~(i) ~~Pacific time on June 30~~injectability, ~~2026,~~meaning ~~one~~it ~~additional~~can ~~transferable~~flow ~~common~~through ~~stock~~a ~~purchase~~fine-gauge ~~warrant~~needle ~~(each, an "Incentive Warrant")~~ for ~~each~~precise ~~Program~~placement; ~~Warrant~~and ~~exercised. Each Incentive Warrant will entitle the holder thereof to purchase one additional share of common stock of the Company~~ (~~each, an "Additional Warrant Share"~~ii) ~~for~~volumizing aperformance, ~~period~~meaning ofit 36can ~~months~~hold ~~from~~shape ~~the~~and ~~date~~fullness ofafter ~~issuance~~placement. ofCXU™ ~~such~~met ~~Incentive~~both ~~Warrant,~~benchmarks. atFull an12-month ~~exercise~~results ~~price~~are ofbeing ~~$2.30~~prepared ~~per~~for ~~Additional~~peer-reviewed ~~Warrant Share~~publication.

On• The ~~June~~demand 4,driver. ~~2026,~~The ~~416~~GLP-1 weight-loss drug market,~~667~~ ~~Incentive~~the ~~Warrants~~category ~~were~~behind ~~issued~~Ozempic® toand ~~the~~Wegovy®, ~~one~~reached ~~Warrant~~roughly ~~holder.~~$79 ~~Following~~billion ~~exercise~~in of2025 ~~the~~and ~~Warrants,~~is aprojected ~~total~~to ofmore ~~410,338~~than ~~Program~~double ~~Warrants~~to ~~remain~~approximately ~~outstanding~~$190 billion by 2035.²,³

~~Subsequent~~• The toopening. ~~the~~The ~~exercise~~same ofweight-loss ~~the~~wave ~~Warrants,~~driving ~~there~~GLP-1 adoption has also exposed a tissue-restoration gap that today's aesthetics tools were 26not specifically designed to fill. That market gap is expected to nearly triple,~~658,330~~ ~~shares~~from ofapproximately ~~common~~$0.7 ~~stock~~billion ~~outstanding~~to $2. 0 billion by 2030.³,⁴

~~The~~• One ~~Warrant~~platform, ~~Shares~~ and ~~Incentive~~a ~~Warrants~~faster ~~were~~first ~~issued~~path. ~~upon~~CXU™ ~~exercise~~is ofbeing ~~the~~developed ~~Warrants~~as ina ~~transactions~~platform, ~~exempt~~not ~~from~~a ~~the~~single ~~registration~~product. ~~requirements~~It ofis ~~the~~based ~~United~~on ~~States~~one ~~Securities~~formulation ~~Act~~protected ofby ~~1933,~~a asmulti-jurisdictional ~~amended~~patent (estate spanning more than 40 jurisdictions, including the "U.S., ~~Securities~~EU, ~~Act")~~Japan, and Australia, with protection pending in ~~reliance~~Canada. onThe ~~the~~Company ~~exclusion~~plans ~~from~~to ~~the~~enter ~~registration~~through ~~requirements~~a ofpredicate-based ~~the~~510(k) ~~U.S.~~pathway ~~Securities~~in ~~Act~~wound ~~provided~~care, bywhich ~~Rule~~targets ~~903(b)~~a of90-day ~~Regulation~~FDA Sreview ~~thereunder~~rather tothan the ~~non~~multi-Uyear studies typically required for a new category, with submission planned for Q1 2027.S. ~~person~~That first clearance is expected to provide the foundation for the Company's planned expansion into aesthetics.

~~The~~"Our ~~holder~~first ofregulatory ~~the~~step ~~Program~~is ~~Warrants~~a ispredicate-based ~~among~~510(k) ~~the~~in ~~selling~~wound ~~security~~care, ~~holders~~which ~~identified~~is inintended to serve as the ~~Registrant's~~foundation ~~registration~~for ~~statement~~our onplanned ~~Form~~move ~~S-1~~into ~~filed~~aesthetics," ~~with~~said ~~the~~Miles ~~U.S.~~Harrison, ~~Securities~~President and ~~Exchange~~CEO ~~Commission~~of ~~(the~~Conexeu Sciences. "~~SEC")~~GLP-1 ~~pursuant~~is toone of the Udefining medical stories of a generation.S. ~~Securities~~Its ~~Act~~success onhas ~~November~~created ~~28,~~an ~~2025~~entirely ~~(as~~new ~~amended,~~patient ~~the~~profile: ~~"Registration~~people ~~Statement"),~~whose ~~and~~bodies ~~declared~~have ~~effective~~changed byfaster than the ~~SEC~~aesthetics onindustry ~~May~~was ~~11,~~built ~~2026~~to ~~(SEC~~address. ~~File~~We ~~No.~~believe ~~333-291845). The~~no ~~Warrant~~existing ~~Shares~~injectable ~~have~~was ~~been~~designed ~~registered~~specifically for ~~resale~~that ~~pursuant~~gap. This phase of our preclinical program gives us an evidence base to ~~the~~continue ~~Registration~~advancing ~~Statement~~CXU™ toward that opportunity. "

~~The~~- ~~Additional~~2 Warrant Shares underlying the Incentive Warrants have not been and will not be registered under the U.S. Securities Act, or any state securities laws, and will only be issuable upon exercise of the Incentive Warrants in transactions that are exempt or excluded from the registration requirements of the U.S. Securities Act and applicable state securities laws.-

-The 2Catalyst: -What P.R.O.O.F Means

~~Exercise~~P.R.O.O.F, ofor Performance ~~Warrants~~and Regeneration Outcomes of Flowable Collagen, is Conexeu's 12-month preclinical study and an important milestone in the development of the CXU™ platform. It does not represent a commercial launch or regulatory clearance. Instead, it marks the point at which the Company has completed a preclinical evidence package intended to support its continued advancement toward medical aesthetics.

On June 8, 2026, the Company issued 100,000 shares of common stock (the "Performance Warrant Shares") at a price of $0.001 per share upon the exercise of a like number of issued and outstanding performance common stock purchase warrants (the "Performance Warrants"), for gross proceeds of $100. The ~~Company~~Three ~~relied~~Evidence upon the exemption from the registration requirements of the U.S. Securities Act provided by Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder for the issuance of such Performance Warrant Shares to the individual who is a U.S. person.Pillars

~~Subsequent~~Pillar toOne: ~~the~~Facial ~~exercise~~Tissue ~~of the Performance Warrants, there were 26,758,330 shares of common stock outstanding.~~Restoration

~~SECTION~~In 9a small-volume ~~FINANCIAL~~facial ~~STATEMENTS~~application, ~~AND~~the ~~EXHIBITS~~study met its objectives in a cheek model, demonstrating tissue restoration within the parameters established for the study.

Pillar Two: Large-Volume Tissue Restoration

In large-volume subcutaneous tissue, the study met its objectives in a 200cc-equivalent model, demonstrating tissue restoration at volumes relevant to potential future applications.

Pillar Three: Injectable Performance

The injectable aesthetics market has already established the core performance characteristics a material must meet. It must be injectable, meaning it can flow through a fine-gauge needle for precise placement. It must also demonstrate volumizing performance, meaning it can maintain shape and fullness after placement. CXU™ met these predefined performance benchmarks.

"Taken together, these three pillars provide evidence across facial applications, large-volume applications, and injectable performance," Harrison continued. "While additional development and regulatory work remain ahead, this phase of our preclinical program provides an important evidence base supporting the continued advancement of CXU™."

The Milestone Behind the Move

The completed 12-month preclinical study assessed tissue response to the CXU™ platform at multiple timepoints following intradermal and subcutaneous placement in an animal model. The study included histologic assessment of scaffold persistence, host-tissue response, tissue ingrowth, vascularization, integration, and remodeling.

The study included two arms: a small-volume facial arm observed across the full 12 months, and a larger-volume body arm designed to evaluate performance in a higher-volume soft-tissue setting.

The Company intends to submit the results for scientific presentation and peer-reviewed publication. To preserve the integrity of that process, Conexeu is not disclosing detailed findings, quantitative analyses, or individual histologic endpoints at this time.

- 3 -

A Platform, Not a Single Product

Conexeu is building CXU™ as one formulation and one platform, with an intellectual property strategy designed to match that approach. The core formulation is designed to provide a temporary structural environment that a patient's own tissue can populate. The Company's IP strategy is built around that single formulation rather than any one indication.

The hypothesis under evaluation is that this property is not limited to skin. The same scaffold designed to support dermal remodeling in facial tissue is also designed to support host-tissue ingrowth in other soft-tissue settings where a conforming scaffold is placed.

That single formulation is the asset. The same platform has been studied across soft-tissue applications, including wound care and dental soft tissue, with continued preclinical work in additional settings. Each application represents a distinct investigational direction, while sharing the platform's formulation and IP backbone.

The Company is advancing its completed data package toward scientific presentation and peer-reviewed publication. Its first regulatory step is a predicate-based 510(k) submission for its lead wound care device candidate, targeted for Q1 2027, subject to the completion of required testing, manufacturing activities, and regulatory documentation.

Subject to FDA review and clearance, wound care is expected to serve as the Company's initial commercial indication and the foundation from which Conexeu intends to expand the CXU™ platform into additional applications, including medical aesthetics.

A copy of the news release is attached as Exhibit 99.1 hereto.

The information contained in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit		Description
99.1		News Release dated July 7, 2026
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

- 34 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CONEXEU SCIENCES INC.
DATE: June 9, 2026	By:	/s/ Stephen Inouye
DATE: July 7, 2026	By:	/s/ Stephen Inouye
		Stephen Inouye
		CFO, Secretary and Treasurer

~~- 4 -~~__________

- 5 -

Filing Compare · Conexeu Sciences Inc.